© 2017 Pharmstandard Ventures

Our Team

We are an ambitious team of professionals with comprehensive experience in academic and biopharmaceutical industry, drug discovery and development, venture investments. We are dedicated to investing in breakthrough drug development projects worldwide.

Our Team

We are an ambitious team of professionals with comprehensive experience in academic and biopharmaceutical industry, drug discovery and development, venture investments. We are dedicated to investing in breakthrough drug development projects worldwide.
Head of Pharmstandard Ventures
Head of Investment Analysis
Head of Expert Department


Head of Pharmstandard Ventures
Alexey Vinogradov, Ph.D.
Dr Vinogradov has over 15 years of experience at different positions in biotech industry, including R&D, operations, management and business development. He has served as a Board member at Argos Therapeutics and Board observer at Protagonist Therapeutics and Aquinox Pharmaceuticals, and currently serves as Board member at Avelas Biosciences and TearSolutions.

Prior to joining Pharmstandard Ventures (formerly Inbio Ventures) in 2012 as co-founding partner and CBO, Dr. Vinogradov was involved in portfolio building at Bioprocess Capital Partners, Russia's first specialized life sciences Venture fund. He led the fundraising and served in executive management at Promogene, Tartis-oncology and Everon. In addition, Dr. Vinogradov was involved in the range of business development activities at Bioprocess Group, one of the pioneers at Russian biosimilars market (more recently acquired by Pharmstandard).

Dr Vinogradov held postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, the Netherlands. He obtained his PhD degree in biochemistry and MS degree in chemistry from Moscow State University.
Head of Investment Analysis
Elena Starikova
Elena has an extensive experience in evaluating investment opportunities in biopharmaceutical industry. Since joining Pharmstandard Ventures (formerly Inbio Ventures) in 2014, she was involved in looking for new projects, financial modeling, deal structuring as well as analysis of portfolio companies' performance. She currently serves as a Board observer at TearSolutions.

Prior to Pharmstandard Ventures Elena worked as an Investment Manager in Bioprocess Capital Ventures, one of the first Russian venture funds specialized in life science. Earlier in her career Elena held several positions in consulting companies, including Roland Berger Strategy Consultants.

Elena graduated from Plechanov Russian University of Economics with honors. She received her MA in economics and mathematics with focus on risk management.
Head of Expert Department
Petr Denisov, Ph.D., M.D.
Before joining Pharmstandard Ventures (formerly Inbio Ventures), Petr Denisov served as business development director, feasibility manager and clinical project manager at different contract research organizations (WWCT, SRG). Petr has ten years of experience in clinical trials (protocol-based feasibility studies in different areas of medicine and more than 40 countries), 4 years of experience in non-clinical trials, 5+ years of experience in Emergency medicine, 5 years of project management and medical monitoring experience in local clinical trials (pulmonology; bioequivalence studies; oncology; cardiovascular diseases). He received his M.D. from Saint-Petersburg State Medical University n.a. I.P.Pavlov in 1996, and got a Ph.D. degree in normal physiology from the Department of Visceral Systems of the Institute of Experimental Medicine (Saint-Petersburg, Russia). His Ph.D. work was devoted to physiology of blood circulation.
Lead Expert
Nataliya Mushenkova, Ph.D.
Natalya has extensive experience in molecular biology, genetic engineering and cellular biology, deep knowledge of oncology, carcinogenesis, immunology, pharmaceutical drug development. Before joining Pharmstandard Ventures (formerly Inbio Ventures), Natalya Mushenkova served as a scientific expert at IBC Generium since 2010. She received her Ph.D. in Immunology and Molecular Bilology from Institute of Bioorganic Chemistry. Her Ph.D. work was devoted to the development of muc-1 specific vaccine and study of its anti-tumor effects in mice. She graduated from Moscow State University, she was a student of educational program "Oncoimmunology the 3rd Millenium" sponsored by CRI.
Expert
Anton Vyatchanin, Ph.D.
Anton Vyatchanin was previously a scientific expert at IBC Generium since 2011. His main activity was focused on scientific assessment of incoming projects and management several of those that have been approved to be developed within the company. Before that he participated in development of several biologics in CJSC Biocad as a project leader within biochemical part of the projects.

He got a Ph.D. in biochemistry from Institute of Gene Biology RAS in 2008 after he graduated from Biology faculty of Moscow State University in 2005. His Ph.D. work was devoted to phage-display selection of mini-antibodies from libraries of single-chain antibodies of two-humped camels. His experience relates to protein biochemistry, molecular biology, biological drug development.
Expert
Svetlana Aleeva, Ph.D.
Before joining Pharmstandard Ventures (formerly Inbio Ventures), Svetlana served as a head of preclinical research department at IBC Generium, a Russian biotechnology company, since 2012. During this time, under her supervision more than 20 preclinical research programs of potential drugs were developed and carried out, whereas some of them have already successfully entered the stage of clinical evaluation. Previously she worked in the field of somatic stem cell nuclear transfer for obtaining the embryonic stem cells without using of human oocytes, and she has developed a technology of efficient reprogramming of human somatic stem cells to a pluripotent state.

Svetlana has more than 8 years of experience in stem cell biology and tissue engineering (creation of human bone, cartilage and skin), in 2007 she received Ph.D. in Immunology and Biotechnology. Her Ph.D. work was devoted to the evaluation of human stem cells from adipose tissue, the creation of three-dimensional structures of human cartilage tissues with the assessment of potential clinical application for regenerative medicine. She underwent specialization at Biology faculty of Moscow State University in the field of Molecular Biology in 2001. She has experience in the Department of Surgery and Intensive Care in Emergency hospital after she graduated from Medical college in 1995.
Expert
Alexey Evseev, Ph.D.
Before joining Pharmstandard Ventures (formerly Inbio Ventures) Alexey Evseev did postdoc in University of Texas Medical Center in San Antonio focusing on neuron and muscle physiology, ion channels and cell signaling pathways.

Alexey has extensive experience in cell biology, signaling pathways and general physiology.

He received his Ph.D. from Russian Academy of Sciences in 2010. His Ph.D. work is about mechanism of endocytosis and mechanics of plasma membrane fission. Results of his study are published in Cell journal.